About TBMC
The rapid progress, production, and global distribution of mRNA vaccines have played a pivotal role in combating the effects of COVID-19 worldwide. In the early stages of vaccine rollout, the supply of mRNA vaccines was primarily directed to the countries engaged in their development and production, leading to a temporary shortage of vaccines in Taiwan.
Consequently, a country‘s ability to quickly manufacture advanced biological pharmaceuticals through Contract Development and Manufacturing Organization (CDMO) services is closely linked to protecting the health and welfare of its citizens.
Taiwan Bio-Manufacturing Corporation (TBMC), established in May 2023, specializes in cutting-edge biotechnology, including viral vectors, cell therapies, and protein technologies. Born from collaborations with the Department Center for Biotechnology (DCB) and Industrial Technology Research Institute (ITRI), TBMC is rapidly advancing in biopharmaceutical manufacturing.
With state-of-the-art technologies like Raman spectroscopy and automated cell culturing system, TBMC aims to become Asia's first Pharma 4.0 CDMO, delivering high-quality biologics medicines.
Previous
Next
![TBMC典範複製_英文版__new](https://tbmcbio.com/wp-content/uploads/2024/03/TBMC典範複製_英文版__new.jpg)
![TBMC典範複製_英文版__new2](https://tbmcbio.com/wp-content/uploads/2024/03/TBMC典範複製_英文版__new2.jpg)
Previous
Next
Milestone
![](https://tbmcbio.com/wp-content/uploads/2024/03/0308TBMC網站_milestone調整-1.png)
Operationally ready by July 2024
Process Development Lab Taipei
Bioinnovation Park
1,820 m2
![](https://tbmcbio.com/wp-content/uploads/2024/01/素材-21.jpg)
Expected to be operational by Q3 of 2025
GMP Plant
Hsinchu Biomedical Science Park
15,000 m2
![](https://tbmcbio.com/wp-content/uploads/2024/01/素材-22.jpg)
Operationally ready by July 2024
Process Development Lab Taipei Bioinnovation Park
1,820 m2
![](https://tbmcbio.com/wp-content/uploads/2024/01/素材-21.jpg)
Expected to be operational by Q3 of 2025
GMP Plant
Hsinchu Biomedical Science Park
15,000 m2
![](https://tbmcbio.com/wp-content/uploads/2024/01/素材-22.jpg)
Team
![](https://tbmcbio.com/wp-content/uploads/2024/05/240516董事_楊育民-1-scaled.jpg)
Patrick Yang
Ph. D.
Chairman/ Director of the Board
![](https://tbmcbio.com/wp-content/uploads/2024/03/S__25051192拷貝.jpg)
David Chang
Ph. D.
CEO
![](https://tbmcbio.com/wp-content/uploads/2024/01/04-特聘顧問_吳忠勳.jpg)
Herbert Wu
Ph. D.
Executive Advisor
![](https://tbmcbio.com/wp-content/uploads/2024/01/05-策略長_紀威光.jpg)
Wei-Kuang Chi
Ph. D.
CSO
![](https://tbmcbio.com/wp-content/uploads/2024/06/耀華logo-1.jpg)
Yao-Hwa Co., Ltd Management Commission
Vice Chairman/ Director of the Board
![](https://tbmcbio.com/wp-content/uploads/2024/01/董事長_瞿志豪.jpg)
Michel Chu
CFO / Director of the Board
Representative of the Industrial Technology Investment Corporation
![](https://tbmcbio.com/wp-content/uploads/2024/01/02-董事_戴建丞.jpg)
Chien-Cheng Tai
Ph. D.
Director of the Board
Representative of the National Development Fund Management Committee
![](https://tbmcbio.com/wp-content/uploads/2024/01/01-董事_蘇來守.jpg)
Lai-Shou Su
Director of the Board
Representative of the National Development Fund Management Committee
![](https://tbmcbio.com/wp-content/uploads/2024/01/董事_Rahul-Singhvi-ScD先隱藏.jpg)
Rahul Singhvi, SC.D.
Director of the Board
Representative of RTW23, LLC
![](https://tbmcbio.com/wp-content/uploads/2024/01/03-監察人_曾惠瑾.jpg)
Audrey Tseng
Supervisor
![](https://tbmcbio.com/wp-content/uploads/2024/01/06-核酸製劑處處長_林瓊.jpg)
King Lam
Ph. D.
Nucleic Acid Div.
Director
Director
![](https://tbmcbio.com/wp-content/uploads/2024/01/08-生物製劑處副處長_滕昭怡.jpg)
Joyce Teng
Ph. D.
Biologics Div.
Deputy Director
Deputy Director
![](https://tbmcbio.com/wp-content/uploads/2024/01/team_楊靜仁.jpg)
Ching-Jen Yang
Ph. D.
Gene Therapy Div.
Deputy Director
Deputy Director
![](https://tbmcbio.com/wp-content/uploads/2024/01/TBMC_團隊成員無照片顯示-scaled.jpg)
Hsien-Yu Tsai
Ph. D.
Analytic Development Div.
Deputy Director
Deputy Director
![](https://tbmcbio.com/wp-content/uploads/2024/01/TBMC_團隊成員無照片顯示-scaled.jpg)
Hsin-Hsin Shen
Ph. D.
Cell therapy Div.